Pharmacy

The aging population and the huge unmet needs are fueling the focus on biologics, according to a new report from PricewaterhouseCoopers (PwC).

In the wake of healthcare reform, pharmaceutical executives help take charge.

The disparity in coverage between oral and IV chemotherapy medication is a critical issue for patients and is being debated at the national and federal levels.

Wal-Mart pharmacy programs has industry rethinking benefit approaches.

For personalized therapies to be incorporated into a plan's coverage, a commercially insured enrollee would need to stay with the plan for many years, as more expensive therapies require longer member retention to break even, according to Deloitte.

United says it has no plans to follow suit by selling off its pharmacy benefit services. WellPoint will oursource now.

Prescription drug trends show that the underinsured may be voluntarily opting out of compliance due to affordability issues. Lower copayments may be key to curbing this.

University of South Florida and Allscripts push paper-free prescribing while touting the availability of stimulus funding for e-health.

Heart disease is considered the costliest condition, outranking cancer. Some 80 million people require care for coronary heart disease

Specialty drugs bring about the need for a sales force with more clinical knowledge

WellPoint decision to sell off its PBM business is seen by experts as good, strategic move for the health insurer.

Group sessions can also empower patients to cope with recurrence of painful headaches

One of the main criticisms of consumer-directed health plans questions whether members avoid needed medications to save money

Pfizer-Wyeth union is just another example of consolidation in the pharma industry.

Lobbying efforts by the pharmaceutical industry and timing concerns have prevented CMS from requiring that all Part D plans move to pass-through pricing

WellPoint sanctions might be indicative of deeper oversight problems in Medicare.

Although there are barriers to childhood and adult vaccines, benefits likely outweigh the risks, so health plans must be in the driver's seat as far as education and delivery of care.

The first step towards creating an effective market access function is to develop a clear understanding of the needs and perspectives of the various stakeholders in each individual market

Two pricing bases could be identified as potential future replacements for AWP, namely average sales price (ASP) and average manufacturer price (AMP)

Pharmacogenomics offer value measures to MCOs as specialty drug costs skyrocket.

CMS is sending a message that all prescribers must begin using electronic tools to increase safety and reduce costs. Commerical payers are onboard.

PPIs and H2 -receptor blockers are standard treatment for peptic ulcers and GERD, but lifestyle changes and OTC products can help

If MAC lists were not in place, prices for drugs would vary dramatically. Discounts for generic drugs would also decrease significantly.

Does it make sense to treat children for conditions, such as high cholesterol, type 2 diabetes and hypertension, with drugs that have only been approved for adults? If the potential benefit to the child is outweighed by the risk of harm or adverse events, then it makes sense, experts say.

Moving forward, the challenge for health plans and their clients will be to create value as opposed to simply shifting costs to enrollees. Creative solutions abound.

Drug store consolidation leads to increased pressure on retail pharmacies -- and certain drug store chains will not survive

Will generic drugs, patent expirations, safety issues and a dry pipeline for high-incident diseases make room for a new drug paradigm?

Specialty pharmacy as a managed benefit has arrived at the same place pharmacy benefit management was several years ago (offering open formularies, flat co-pays, etc.). Yet little is being done to address specialty pharmacy as a managed benefit.

A recent online survey from Serono Injectables Digest, which includes data from 83 health plans, looked at the challenges and strategies of managing specialty pharmacy, provider reimbursement and cost sharing.

Drug trend for 2007 was 2%, the lowest year-over-year trend since Medco began tracking it in 1999, according to the company. While the drug cost trend is small in terms of overall healthcare dollars spent, it was at one time rising at a rate more than double the rate of inflation, according to Lon Castle, MD, senior director, department of medical and analytical affairs at Medco.